Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$250.69
-1.2%		$223.60
$138.00
▼
$254.41
$37.51B0.091.30 million shs1.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,275.50
-2.4%		$1,186.64
$809.63
▼
$1,321.21
$1.23T0.462.30 million shs2.27 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-1.24%+7.75%+10.18%+23.99%+69.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.50%+1.39%+10.56%+6.63%+57.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$250.69
-1.2%		$223.60
$138.00
▼
$254.41
$37.51B0.091.30 million shs1.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,275.50
-2.4%		$1,186.64
$809.63
▼
$1,321.21
$1.23T0.462.30 million shs2.27 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-1.24%+7.75%+10.18%+23.99%+69.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.50%+1.39%+10.56%+6.63%+57.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.63
Moderate Buy$241.89-3.51% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.86
Moderate Buy$1,317.933.33% Upside

Current Analyst Ratings Breakdown

Latest BIIB and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/22/2026
Biogen Inc. stock logo
BIIB
Biogen
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$219.00 ➝ $244.00
10/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$1,309.00 ➝ $1,316.00
10/21/2026
Biogen Inc. stock logo
BIIB
Biogen
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$225.00 ➝ $250.00
10/20/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$1,413.00
10/20/2026
Biogen Inc. stock logo
BIIB
Biogen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$250.00 ➝ $310.00
10/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (B) ➝ Buy (B+)
10/12/2026
Biogen Inc. stock logo
BIIB
Biogen
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform$220.00
10/12/2026
Biogen Inc. stock logo
BIIB
Biogen
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Overweight$210.00 ➝ $300.00
10/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$1,500.00
10/9/2026
Biogen Inc. stock logo
BIIB
Biogen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$240.00 ➝ $270.00
10/8/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$260.00 ➝ $256.00
(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.74$22.34 per share11.22$124.45 per share2.01
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B18.42$24.54 per share51.98$28.07 per share45.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6544.3715.572.838.32%11.18%6.88%10/28/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8042.8027.011.7433.53%97.83%23.23%10/29/2026 (Estimated)

Latest BIIB and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.70N/AN/AN/A$22.58 billionN/A
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.97N/AN/AN/A$2.63 billionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.54%+15.18%23.22%11 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable

Recent News About These Companies

Best Pharmaceutical Stocks To Watch Today - October 24th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-best-pharmaceutical-stocks-to-watch-today-october-24th-2026-10-24/
Eli Lilly's Next-Generation Ovarian Cancer Drug Shows 79% Response Rate, 100% Disease Control In New Data
 |  stocktwits.comS
Eli Lilly and Company $LLY Shares Sold by USAdvisors Wealth Management LLC
October 24 at 9:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-shares-sold-by-usadvisors-wealth-management-llc-2026-10-24/
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space
October 24 at 7:06 AM  |  fiercebiotech.comF
Eli Lilly and Company: Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRa-targeting ADC at ESMO 2026
October 24 at 7:06 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69925789-eli-lilly-and-company-lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cancer-for-its-investigational-next-generation-fra-targeting-008.htm
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
October 24 at 7:06 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lilly-presents-first-clinical-data-063000212.html
Eli Lilly CEO previews the next generation of weight-loss drugs
October 24 at 4:00 AM  |  youtube.comY
Eli Lilly (LLY) Stock: Slips 2.54% Despite Promising Phase 1 Ovarian Cancer Results
October 24 at 3:31 AM  |  blockonomi.comhttps://blockonomi.com/eli-lilly-lly-stock-slips-2-54-despite-promising-phase-1-ovarian-cancer-results/
Eli Lilly and Company $LLY Shares Sold by Essential Planning LLC.
October 24 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-shares-sold-by-essential-planning-llc-2026-10-24/
7,473 Eli Lilly and Company $LLY Shares Sold by Halter Ferguson Financial Inc.
October 24 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-7473-eli-lilly-and-company-lly-shares-sold-by-halter-ferguson-financial-inc-2026-10-24/
Axxcess Wealth Management LLC Sells 12,282 Shares of Eli Lilly and Company $LLY
October 24 at 3:22 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axxcess-wealth-management-llc-sells-12282-shares-of-eli-lilly-and-company-lly-2026-10-24/
Eli Lilly and Company $LLY Stock Purchased by Crossmark Global Holdings Inc.
October 24 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-stock-purchased-by-crossmark-global-holdings-inc-2026-10-24/
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
October 24 at 2:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cancer-for-its-investigational-next-generation-fr-targeting-adc-at-esmo-2026-302918153.html
Goldman Sachs rates Eli Lilly buy, lifts 12-month price target ahead of earnings
October 23 at 8:23 PM  |  msn.comhttps://www.msn.com/en-us/news/money/goldman-sachs-rates-eli-lilly-buy-lifts-12-month-price-target-ahead-of-earnings/ar-AA2fW6n0
Eli Lilly and Company (NYSE:LLY) Stock Falls 2.4% - Should You Sell?
October 23 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-eli-lilly-and-company-nyse-lly-stock-falls-24-should-you-sell-2026-10-23/
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)
October 23 at 3:45 PM  |  fool.comhttps://www.fool.com/investing/2026/10/23/2-growth-stocks-to-hold-for-the-next-decade-hint-these-aren-t-ai-stocks/
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability Leader
October 23 at 3:21 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/b4b4d4d0-0d84-3a6a-8c39-f57c522e66d1/eli-lilly%27s-fast-growth.html
Polen Focus Growth Strategy Trims Eli Lilly and Company (LLY) While Maintaining Confidence in Its Outlook
October 23 at 3:21 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/polen-focus-growth-strategy-trims-150556189.html
JP Morgan Expects Emerging Market Weight Loss Drug Sales To Reach $22 Billion
October 23 at 3:21 PM  |  tikr.comT
Eli Lilly (LLY) Builds In Richmond As Fair Value Still Sits Higher
October 23 at 3:21 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/eli-lilly-lly-builds-richmond-181116184.html
Pharmaceutical Stocks To Follow Now - October 23rd
October 23 at 1:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-pharmaceutical-stocks-to-follow-now-october-23rd-2026-10-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Kalshi and Polymarket logos beside a smartphone showing a prediction market on the Chiefs winning the Super Bowl, with a football in the background.
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
By Jessica Mitacek | October 8, 2026
Close-up of an Nvidia logo on a computer chip mounted on a circuit board with cables and hardware components.
NVIDIA Just Strengthened the Case for Its Massive Stock Price Upside
By Thomas Hughes | September 29, 2026
Television displaying the Netflix logo in a dark living room with a coffee table, popcorn bowl, and remote.
Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
By Sam Quirke | September 30, 2026
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
By Bridget Bennett | October 19, 2026
Biogen stock logo

Biogen NASDAQ:BIIB

$250.69 -3.15 (-1.24%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$251.12 +0.43 (+0.17%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,275.50 -31.19 (-2.39%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$1,278.93 +3.43 (+0.27%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas